EMAIL THIS PAGE TO A FRIEND

PloS one

Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.


PMID 24686948

Abstract

Pathological destruction of blood-brain barrier (BBB) has been thought to be the initial key event in the process of developing multiple sclerosis (MS). The purpose of the present study was to clarify the possible molecular mechanisms responsible for the malfunction of BBB by sera from relapse-remitting MS (RRMS) and secondary progressive MS (SPMS) patients. We evaluated the effects of sera from the patients in the relapse phase of RRMS (RRMS-R), stable phase of RRMS (RRMS-S) and SPMS on the expression of tight junction proteins and vascular cell adhesion protein-1 (VCAM-1), and on the transendothelial electrical resistance (TEER) in human brain microvascular endothelial cells (BMECs). Sera from the RRMS-R or SPMS patients decreased the claudin-5 protein expression and the TEER in BMECs. In RRMS-R, this effect was restored after adding an MMP inhibitor, and the MMP-2/9 secretion by BMECs was significantly increased after the application of patients' sera. In SPMS, the immunoglobulin G (IgG) purified from patients' sera also decreased the claudin-5 protein expression and the TEER in BMECs. The sera and purified IgG from all MS patients increased the VCAM-1 protein expression in BMECs. The up-regulation of autocrine MMP-2/9 by BMECs after exposure to sera from RRMS-R patients or the autoantibodies against BMECs from SPMS patients can compromise the BBB. Both RRMS-S and SPMS sera increased the VCAM-1 expression in the BBB, thus indicating that targeting the VCAM-1 in the BBB could represent a possible therapeutic strategy for even the stable phase of MS and SPMS.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB4200537
Anti-Claudin-5 antibody produced in rabbit, ~1.0 mg/mL, affinity isolated antibody
SAB2100442
Anti-CLDN5 antibody produced in rabbit, affinity isolated antibody
SAB1406198
Anti-OCLN antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA005933
Anti-OCLN antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB3500301
Anti-OCLN antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2103797
Anti-OCLN, (N-terminal) antibody produced in rabbit, affinity isolated antibody
WH0007122M1
Monoclonal Anti-CLDN5 antibody produced in mouse, clone 3D8, purified immunoglobulin, buffered aqueous solution
WH0004950M1
Monoclonal Anti-OCLN antibody produced in mouse, clone 1G7, purified immunoglobulin, buffered aqueous solution
AMAB90893
Monoclonal Anti-OCLN antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1608, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90890
Monoclonal Anti-OCLN antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1567, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90889
Monoclonal Anti-OCLN antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1555, purified immunoglobulin, buffered aqueous glycerol solution